Umme Sabrina Haque is currently serving as a Basic Science Trainee Committee member within the NMD4C, contributing to SOP development. She is a neuromuscular researcher and PhD candidate in the Yokota lab at the University of Alberta, specializing in antisense oligonucleotide (ASO) and CRISPR/Cas‑based therapeutic approaches for spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and giant axonal neuropathy, with a focus on developing safe, non‑invasive delivery strategies that enable central nervous system and multi‑organ therapeutic rescue.